Live Breaking News & Updates on ரோன் ஆண்ட்ரூஸ்|Page 2

Stay updated with breaking news from ரோன் ஆண்ட்ரூஸ். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

(OCX) - Why OncoCyte Shares Are Trading Higher Today

OncoCyte Corp (NYSE: OCX) shares are advancing to their highest level since the middle of 2019 on above-average volume.
Oncocyte said it has entered into . ....

Ron Andrews , Pura Vida , Oncocyte Corp , Pura Vida Investments , Broadwood Partners , ரோன் ஆண்ட்ரூஸ் , பூரா விடா , பூரா விடா முதலீடுகள் , அகன்ற மரம் கூட்டாளர்கள் ,

Oncocyte Announces $25 Million Registered Offering

Oncocyte Announces $25 Million Registered Offering
Offering Led by Current Shareholder and Healthcare Investor, Pura Vida Investments, Substantially Increasing Its Holdings
Further Strengthens Balance Sheet to Support Ongoing Commercial and Development Activities across Cancer Care Continuum
IRVINE, Calif., Jan. 20, 2021 Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has entered into definitive agreements with its two largest institutional investors to purchase approximately $25 million of Oncocyte’s common shares in a registered offering priced at $3.424 per share (“at market”), which was the average of the last five closing prices. The lead investor in the offering, Pura Vida Investments, LLC, a fundamentally driven, healthcare-focused registered investment advisor, increases its ownership of Oncocyte f ....

United States , United Kingdom , Determa Mx , Ron Andrews , Pura Vida , Development Activities , Office Of Oncocyte , Company Determa , Oncocyte Corporation Form , Exchange Commission , Oncocyte Corporation , Phd Lifesci Communications , Investor Contact Bob Yedid Lifesci Advisors , Its Holdings , Pura Vida Investments , Offering Led , Current Shareholder , Healthcare Investor , Substantially Increasing Its , Strengthens Balance Sheet , Support Ongoing Commercial , Cancer Care , Broadwood Partners , Chief Executive Office , Managing Member , Contact Bob Yedid Lifesci Advisors ,

Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China

Oncocyte and Burning Rock Execute Strategic Agreement to Distribute DetermaRx in China
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.

United States , Yusheng Han , Ron Andrews , Bob Yedid , Lifesci Advisors , United States National Comprehensive Cancer Network , Exchange Commission , Oncocyte Corporation , Lifesci Communications , Burning Rock Biotech Limited , Chronix Biomedical Inc , Burning Rock Biotech , Burning Rock , Chief Executive Officer , Exclusive Sublicense Agreement , Chronix Biomedical , Rock Biotech Limited , Sci Advisors , Sci Communications , America International Association , Lung Cancer Conference , ஒன்றுபட்டது மாநிலங்களில் , ரோன் ஆண்ட்ரூஸ் , ஒன்றுபட்டது மாநிலங்களில் தேசிய விரிவான புற்றுநோய் வலைப்பின்னல் , பரிமாற்றம் தரகு , எரியும் பாறை பயோடெக் வரையறுக்கப்பட்டவை ,

OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares

Shares of OncoCyte Corp.
OCX,
-1.98%
rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement with China-based Burning Rock Biotech Ltd.
BNR,
-0.72%
to bring OncoCyte s DetermaRX test for early-stage lung cancer patients to China. Trading volume spiked to 8.3 million shares, compared with the full-day average of about 419,500 shares. This agreement with Burning Rock accelerates the ongoing expansion of our DetermaRx test to patients and physicians outside the U.S., and exemplifies our global growth strategy, said OncoCyte Chief Executive Ron Andrews. The news and stock s rally comes as several OncoCyte executives and directors disclosed that they acquired shares on Dec. 11, as repayment of deferred compensation in lieu of cash at a price of $2.07 per share, which was 2.4% below Monday s closing price. T ....

Oncocyte Determa , Ron Andrews , Burning Rock Biotech Ltd , Oncocyte Corp , China Based Burning Rock Biotech , Burning Rock , Oncocyte Chief Executive Ron , ரோன் ஆண்ட்ரூஸ் , எரியும் பாறை பயோடெக் லிமிடெட் , சீனா அடிப்படையிலானது எரியும் பாறை பயோடெக் , எரியும் பாறை ,

Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China – IT Business Net

Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United States , San Francisco , Yusheng Han , Ron Andrews , University Of California , Company Or Burning Rock , Oncocyte Corporation , Burning Rock Biotech Limited , Securities Exchange , Kaiser Permanente Northern California , Burning Rock , Chief Executive Officer , Rock Biotech Limited , Securities Exchange Act , Securities Litigation Reform Act , America International Association , Lung Cancer Conference , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , ரோன் ஆண்ட்ரூஸ் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , நிறுவனம் அல்லது எரியும் பாறை , எரியும் பாறை பயோடெக் வரையறுக்கப்பட்டவை , பத்திரங்கள் பரிமாற்றம் , கைசர் நிரந்தர வடக்கு கலிஃபோர்னியா , எரியும் பாறை ,